|Articles|February 19, 2014
LCGC TV: Koen Sandra on Analyzing Protein Biopharmaceuticals Using LC–MS
By 2020, more than 50% of approved drugs are expected to be protein biopharmaceuticals. Koen Sandra from the Research Institute for Chromatography in Belgium discusses the challenges of characterizing protein biopharmaceuticals and why LC–MS is now indispensable for characterizing this class of drugs.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on LCGC International
1
HPLC, PTR-ToF-MS Enable AI Grading of White Tea
2
Analytical Procedure Lifecycle Approaches in Accordance With ICH Q14 and ICH Q2(R2): Opportunity Knocks or Just Another Challenge and Headache? (Part 2)
3
LC-MS/MS Links Vitamin D Levels to Sleep Timing
4
Highlights from the HPLC2026 Conference through the Lens of LC Troubleshooting
5